Podcasts about c2i

Marc Stapley, CEO at Veracyte, joins OPTO Sessions to discuss the company's use of AI and machine learning, its strategic focus on the cancer diagnostics cycle, and how its acquisition of MRD platform C2i expands this focus to the post-treatment phase. Enjoy!-----The content in this podcast is for informational purposes only. Opto Markets LLC does not recommend any specific securities or investment strategies. Investing involves risk & investments may lose value, including the loss of principal. Past performance does not guarantee future results. Investors should consider their investment objectives and risks carefully before investing. The information provided is not an endorsement of this product and is for information and/or educational purposes only.

Episode 4 (January 12, 2024): Takeaways from the J.P. Morgan Health Care conference: Illumina, Danaher, 10x, Empress Therapeutics; an interview with Liberate Bio's Shawn Davis and Walter Strapps. Listed below are references to relevant GEN stories discussed in this episode of Touching Base: JPM: Illumina's new CEO spells out 2024 priorities, presents preliminary Q4 2023 results By Alex Philippidis, GEN, January 10, 2024. JPM: Prime Medicine eyes 2024 IND for first prime editing therapy By Alex Philippidis, GEN, January 9, 2024 JPM 2024: Veracyte's C2i genomics acquisition adds AI readouts to liquid biopsy testing By Jonathan D. Grinstein, GEN, January 8, 2024 JPM: More M&A “firepower” in store for 2024, EY predicts By Alex Philippidis, GEN, January 8, 2024 Hosted on Acast. See acast.com/privacy for more information.

02:29 Labiotech.eu news04:11 C2i Genomics22:31 Advanced Therapies Congress31:37 BioAlps47:29 Bionter54:06 JLLThe guests on our podcast this week are: Jessica Robinson, project director, Advanced Therapies Congress, Terrapinn: Tobias Werk, CEO, Bionter; Asaf Zviran, CEO and co-founder of C2i Genomics; and Magali Bischof, secretary general of BioAlps.We also have our weekly commentary from Travis McCready at global commercial real estate services company JLL.This week's podcast is sponsored by Bionter, a Swiss-based premier supplier of analytical testing solutions to support Pharma companies to bring drugs faster and safer onto the market. Their first product is a fully automated particle testing device for parenteral drug applications that is cost-efficient and compliant with current regulations. If you want to know more, go to www.Bionter.com.C2i Genomics Announce Successful Evaluation of Whole Genome-Based Residual Disease Test Across Multiple Solid Cancer modelsC2i Genomics, a cancer intelligence company, recently announced an extension of a collaboration with AstraZeneca. The two companies have collaborated to evaluate the potential of whole-genome minimal residual disease (MRD) testing across solid cancers, with the goal of enhancing oncology treatment, supporting clinical trial recruitment, and monitoring. C2i genomics has completed AstraZeneca's BeyondBio Innovation Hub's program for Israeli start-ups. Using artificially generated samples to reproduce varying levels of circulating tumor DNA (ctDNA) expected to be found in tumors, this collaboration provided early evidence that the C2i assay can sensitively detect ctDNA (down to 0.002% allelic frequency). Building on this work, AstraZeneca will further evaluate and validate the C2i Genomics platform across a panel of patient-derived samples using their in-house sequencing capabilities and expertise.The non-invasive detection of circulating tumor DNA (ctDNA) from plasma has been shown to have clinical value for the detection of Minimal Residual Disease (MRD), the emergence of resistance, and the prediction of treatment response. New MRD technologies aim to provide greater cancer detection sensitivity by expanding methods beyond small, personalized panels. C2i Genomics' MRD technology applies whole-genome sequencing and artificial intelligence to a small blood sample to provide ultra-sensitive cancer detection. This technology aims to eliminate the need to develop a patient-specific assay, enabling high-performance, personalized monitoring and rapid turnaround across multiple solid cancers with reduced operational complexity.Advanced Therapies CongressThe Advanced Therapies Congress is Europe's largest cell and gene therapy conference and exhibition. Presented by Terrapinn, the event is for the leaders of the world's ATMP developers and their most senior executives in charge of the latest tech and strategies driving the industry forward. The event takes place on March 14 and 15 at the ExCeL in London.BioAlpsBioAlps is the life sciences cluster covering western Switzerland.It comprises an ecosystem of research institutions, academic institutions, startup companies and large multinationals concentrated in a small,  geographic area.Its aim is to promote western Switzerland as a world class centre for life sciences and to foster growth by creating synergies between academia, entrepreneurs, investors, authorities and new businesses. It offers a networking and support opportunities through regional, national and international events, while promoting BioAlps on the global stage.Interested in sponsoring episodes of the podcast? Learn more here!

Asaf Zviran is the CEO, CSO, and Co-Founder of C2i Genomics which is both a technology company and a diagnostic company. C2i is providing a decentralized, cloud-based platform that allows global genomic labs, health centers, and pharma companies to do whole-genome sequencing on cancer patient tissue or blood. This technology uses the genomic data to determine the best options for treatment and to monitor treatment response. Asaf explains, "The way that we look at the cancer detection is in a holistic way. We're actually detecting huge amounts of features across the genome in a very, very sensitive and accurate manner. Many clinical trials have been showing that the C2i whole-genome approach is much more sensitive and accurate than any other technology that is currently in development." "Whole-genome, I think is a new category in medical genomics in general. Whole-genome allows us to very comprehensively extract everything, all of the variants, all of the genomic changes, in the patient blood. And then the challenge again is how to use this very comprehensive information to create insight, to create applications. This is exactly what C2i is doing. Basically, we are building out clinically validated software applications that can take the whole-genome data, the whole data from the apps that are working with us, and allow very sophisticated AI signal processing to detect cancer, to monitor treatment response, to predict recurrence." "And we are doing that on a global scale. I can tell you that besides our CLIA-equipped lab in the US, we are working in partnership to deliver these services to other health systems in the US. We are a clinical-approved product in Europe, and starting to do clinical testing and working extensively in Europe. We also have a very strong distribution in the Middle East and Asia. So Israel, Singapore, India, and now going into a new location in Asia." #C2iGenomics #WholeGenome  #WholeGenomeSequencing #PrecisionMedicine #Cancer #Tumors #AI #MedicalGenomics C2i-Genomics.com Download the transcript here

Asaf Zviran is the CEO, CSO, and Co-Founder of C2i Genomics which is both a technology company and a diagnostic company. C2i is providing a decentralized, cloud-based platform that allows global genomic labs, health centers, and pharma companies to do whole-genome sequencing on cancer patient tissue or blood. This technology uses the genomic data to determine the best options for treatment and to monitor treatment response. Asaf explains, "The way that we look at the cancer detection is in a holistic way. We're actually detecting huge amounts of features across the genome in a very, very sensitive and accurate manner. Many clinical trials have been showing that the C2i whole-genome approach is much more sensitive and accurate than any other technology that is currently in development." "Whole-genome, I think is a new category in medical genomics in general. Whole-genome allows us to very comprehensively extract everything, all of the variants, all of the genomic changes, in the patient blood. And then the challenge again is how to use this very comprehensive information to create insight, to create applications. This is exactly what C2i is doing. Basically, we are building out clinically validated software applications that can take the whole-genome data, the whole data from the apps that are working with us, and allow very sophisticated AI signal processing to detect cancer, to monitor treatment response, to predict recurrence." "And we are doing that on a global scale. I can tell you that besides our CLIA-equipped lab in the US, we are working in partnership to deliver these services to other health systems in the US. We are a clinical-approved product in Europe, and starting to do clinical testing and working extensively in Europe. We also have a very strong distribution in the Middle East and Asia. So Israel, Singapore, India, and now going into a new location in Asia." #C2iGenomics #WholeGenome  #WholeGenomeSequencing #PrecisionMedicine #Cancer #Tumors #AI #MedicalGenomics C2i-Genomics.com Listen to the podcast here

Lauréat pour la troisième année consécutive du Palmarès de l'immobilier, Julien Raffin, fondateur et directeur du réseau C2i, répond à une nouvelle interview de Fred Haffner. Il nous parle de la croissance rapide de son réseau, de son ambition de multiplier le nombre d'agences par 2 en 2022, du marché et de sa philosophie de travail.

The team at C2i Genomics is combining cutting-edge genomics and sophisticated AI to provide the world's first whole-genome cancer intelligence platform, transforming the way cancer is monitored and treated. C2i uses a blood test that can detect and quantify tiny amounts of residual cancer to better monitor cancer treatment, progression, and recurrence. NFX was an early stage investor in C2i due to their long-term vision and world-changing technology. Listen to NFX Partner Omri Amirav-Drory talk with Asaf Zviran, Co-founder & CEO of C2i Genomics, about the future of their company, their latest technological breakthroughs, and where the industry is headed in the near future. Asaf and Omri's conversation begins at 11:15 Visit C2i to learn more - https://c2i-genomics.com/

A startup C2i Genomics desenvolveu, por isso, uma solução para um diagnóstico precoce, destinada a hospitais, clínicas e farmacêuticas.A solução baseia-se numa biópsia que requer apenas 2 mililitros de sangue para fazer a sequenciação de todo o genoma. Posteriormente, os médicos podem fazer o upload dos resultados na plataforma (SaaS) da C2i. E através de um algoritmo de inteligência artificial, o genoma é analisado, identificando com rapidez e precisão a presença de células cancerígenas.Com esta informação em tempo real, os médicos antecipam e personalizam o tratamento a prescrever aos doentes.Saiba mais sobre inovação e nova economia em supertoast.pt.

C2i Genomicsは残存病変（がん治療後に残存するごくわずかながん細胞）の感知で100倍敏感なソフトウェアを開発。 C2iのテクノロジーを使うと、医師はDNAをチェックするための採血であるリキッドバイオプシーという血液採取の医療器具をオーダーできる。 そこから全ゲノムを解析してC2iのプラットフォームにアップロードできる。 そしてソフトウェアが配列を調べてがんの存在を示すかすかなパターンを特定し、がんが成長しているのか、あるいは縮小しているのかを検査していく。 ★C2i Genomics https://c2i-genomics.com/ ★TECH CRUNCH JAPANの記事 https://jp.techcrunch.com/2021/04/19/2021-04-15-c2i-a-genomics-saas-product-to-detect-traces-of-cancer-raises-100m-series-b/ ★だいじろうのTwitter（ご意見お待ちしてます！） https://twitter.com/daijirostartup #海外　#スタートアップ　#がん #治療 #血液 #検査 --- Send in a voice message: https://anchor.fm/daijirostartup/message

Physical security and smart buildings software, Spintly raises Rs 4.6 crore in an extended seed round of funding led by Silicon Valley-based Riso Capital, along with SucSEED Indovation Fund from Hyderabad, Chicago-based Nikhan Investments and Keiretsu Forum angel network . Spintly provides SaaS-based physical security solutions which enable smartphone-based door access eliminating the need for key cards and elaborate wiring for access control. They will utilise these funds to boost sales, marketing and research activities in order to enhance their position.C2i, a genomics SaaS product to detect traces of cancer, raises $100M Series B. Using C2i's technology, doctors can order a liquid biopsy, which is essentially a blood draw that looks for DNA. This round of funding will be used to accelerate clinical development and commercialization of the company's C2-Intelligence Platform. Investors that participated in the round include NFX, Duquesne Family Office, Section 32 (Singapore), iGlobe Partners and Driehaus Capital.IBM is acquiring myInvenio, a business automation software provider that specializes in process mining as part of the hyperautomation trend. Financial terms of the deal were not disclosed. The acquisition aligns with IBM CEO Arvind Krishna's effort to pivot the business toward multi-cloud software that drives business automation. The efforts span process mining, RPA, document processing, workflow automation and more. Those various software components integrate with IBM Cloud Pak for Business Automation, and run atop Red Hat OpenShift. The OpenShift software allows IBM's automation packages to run on any public, private cloud or hybrid cloud.

En 2022, la vidéo représentera 82% du trafic mondial d'internet, soit 15 fois plus qu'en 2017. En gros, c'est un million de vidéos visionnées par seconde. Voilà, vous aurez compris que la vidéo est un outil pour obtenir plus de mandats. Comment attirer les vendeurs, suivez les conseils de Julien Raffin, directeur fondateur du groupe C2I. SITES INTERNET : https://event-immo.com https://groupe-c2i.com https://pro.meilleursagents.com/wikimmopro/ https://pro.meilleursagents.com

Business of Health.Well.Fit. - Apostle SB Barber talks with Jessica K. Rogers Executive Director of C2i. Louis J. King, CEO of Summit Academy gave Jessica the opportunity of a lifetime! She has positively impacted youth and families in Minneapolis through various community programs she has led over the last 15 years. Jessica is truly passionate about the mission and work of Connections to Independence because she is a product of foster care herself. Jessica is committed to creating a unique culture and environment for C2i youth and staff to feel like this is more than a place to come to work and participate in programming. It’s a safe place where all staff and youth are valued and considered part of a family. The Mission of Connections to Independence is to provide unique programming and advocacy for foster care youth, ages 15 - 21, to promote a successful and healthy transition to living independently as they reach adulthood.  GMSbuzz & Guest Contact: *Sat, 4.23.16 @2PM. Hats & Pearls Springtime Tea Party 'Take a sip for Civili-Tea w/ Mz. Lola Thomas & Cycle Changers Tickets $20. Georgetown On The River, 5750 East River Rd, Fridley, MN 55432. Call 763-355-7177 *Donate In memory & support of Kirk E. Washington, Jr & Family Legacy *Sat, 5.7.16, 3PM-7PM. 3rd Annual Kentucky Derby Fundraiser for Connections To Independence Youth C2i Food, Fashion, Fun all for a great cause! *Twitter@C2iyouth Send us your questions/comments before, during, after the broadcast. Join us on Twitter@GMNetwork, Facebook@GMNLiveTv, YouTube@GMNLiveTv or Instagram@GMNLiveTv -- SB Barber Morning Show with Apostle Shena SB Barber is produced by ShenaBarber.com and presented by GRACE Media Network.

Super-resolution imaging, the ability to resolve structures well below the diffraction limit, has changed fluorescence microscopy as we know it. Diffraction-unlimited microscopy, termed nanoscopy, is able to image deep inside the cell with a resolution approaching that of electron microscopes. A variety of different methods currently exist, the first proposed and demonstrated technique being stimulated emission depletion (STED) microscopy. In STED microscopy, the resolution limit of a laser scanning microscope is overcome by transiently silencing fluorescence in parts of the focus. Practical implementations of this method are limited by optical aberrations and the characteristics of the fluorophores used. In this thesis, I present a fully working, custom built, 3D dual-color STED microscope. A super-continuum source is used to provide all spectral bands necessary for excitation and efficient depletion to achieve a lateral and axial resolution of ~ 35 nm and ~ 90 nm, respectively. I characterize the system’s performance by imaging colloidal particles and single fluorescent molecules. Its biological applicability is demonstrated by imaging of nuclear pore complexes in U2OS and yeast cells, replication complexes in C2C12 cells, C2 toxin component C2I in HeLa cells and scaffold proteins in chemical synapses of hippocampal neurons. Advice on how to build such a microscope is given in the appendix. In addition, a theory is presented which demonstrates that the resolution of STED microscopes can be further enhanced by using the arrival time of spontaneous emission by time-gating the detection.

Pour préparer le C2i, les étudiants suivent des TD présentiels couplés à une formation en ligne tutorée sur la plateforme. 50 chargés de TD et enseignants interviennent dans les TD C2i. Des chargés de TD témoignent ici sur leur expérience d'une année de formation C2i. Ils expliquent l'expérience qu'elle leur apporte et les avantages de cette formation pour les étudiants. Des étudiants apportent aussi leur témoignage.

Chandler Van Voorhis, Co-Founder and Managing Partner of C2I, LLC, a conservation bank, will kick off our fourth mini-series addressing Leadership Domestic Forest Finance.

Cette conférence s'adresse particulièrement aux étudiants préparant le Certificat informatique et internet de niveau 2 pour les enseignants (C2i2E). Elle porte sur une partie de la compétence A3.3 du référentiel et présente des éléments pour une bonne prise en compte des lois et des exigences d'une utilisation professionnelle des Tice concernant la propriété intellectuelle.

Les évolutions de la loi informatique et liberté vers la loi HADOPI.

Qu'est-ce qu'un format de données, les différents formats.

Principes de codage des caractères.

Cours de codage, consacré aux systèmes de numération.

Principes de codage des images.

Définition, les différentes sortes de logiciels, le système d'exploitation.

Messagerie, listes de diffusion, forum, messagerie instantanée et visioconférence.

La récupération d'information, les courriels et la publicité.

Équipement architecture client - Serveur nom de domaine.

Définition d'un protocole, le protocole IP, les réseaux locaux.

Définition de base de réseaux, caractéristiques générales. Les différentes formes de réseaux. Le raccordement d'un particulier à l'internet.

Principes du Web (jusqu'à langage XML), sites Web (jusqu'à Navigateurs) et recherche d'information.

Présentation des conférences du C2i 2008-2009

Outils pour l’autoformation au C2i

Les domaines de compétences du C2i

Quel est votre profil

Les différentes identités

La gratuité n’est pas la caractéristique des logiciels libres

Identité et courrier électronique

Communication sécurisée, les certificats

Web 2.0, définitions

Définitions et exemples de logiciels libres

les portails Web

Conférence du C2, marketing viral

Questions / réponses

questions/réponses

Conférence du C2i : les logiciels libres

Buzz et canulars, les ressorts du Hoax

Buzz et canulars, une histoire ancienne

Identité numérique : nous sommes tous concernés

Survol des modules B1 et B2 du C2I

Reportage réalisé en Juin 2008 au moment du Séminaire C2i à Nice

ch 1 à 3 de A2 du C2I

Présentation de l’UE Info 1 C2I module A1